Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given
together with hormone therapy in treating patients with relapsed prostate cancer. Androgens
can cause the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by
lowering the amount of androgens the body makes. Temsirolimus may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving hormone therapy together
with temsirolimus may kill more tumor cells